Rexahn Pharmaceuticals Names KCSA Strategic Communications as Investor Relations Counsel
ROCKVILLE, Md.--(BUSINESS WIRE)--
Rexahn Pharmaceuticals, Inc. (AMEX: RNN), a leader in the development of innovative therapeutics for life-threatening and life-debilitating diseases, announced today that it has selected KCSA Strategic Communications, a leading New York-based communications firm, as its investor relations agency.
Working in tandem, KCSA and Rexahn will implement a comprehensive investor relations campaign designed to build greater investor awareness of Rexahn's innovative treatments for cancer, central nervous system disorders and other unmet medical needs. Todd Fromer and Jeffrey Goldberger, Managing Partners at KCSA, will lead the investor relations effort for Rexahn.
"With our leading cancer compound, Archexin(TM), and Zoraxel(TM), for treating erectile dysfunction, already in Phase II trials at multiple locations in the U.S, and with nine U.S. patents including four oncology patents in hand, we believe that Rexahn is at a major tipping point in our development," said Chang H. Ahn, Chief Executive Officer of Rexahn. "We believe this is an opportune time to implement a more aggressive communications program, and chose to partner with KCSA for their proven ability to implement strong communications programs, broad capital markets expertise and experience interacting with micro- and small-cap investors."
Todd Fromer, Managing Partner of KCSA Strategic Communications, commented, "We find Rexahn to be a very exciting biopharmaceutical company that offers investors a unique opportunity to capitalize on a diverse portfolio of extremely promising compounds, with large market opportunities. The Company has remained under the radar of the institutional investment community for some time, but as its compounds continue to successfully progress through clinical trials with stellar results, we believe that Rexahn offers a compelling value opportunity for investors. We look forward to working with management to actively raise awareness of the Company's exciting value proposition."
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain their quality of life. For Additional information about Rexahn visit www.rexahn.com.
Safe Harbor
This press release contains statements (including projections and business trends) that are forward-looking statements. Rexahn's actual results may differ materially from the anticipated results and expectations expressed in these forward-looking statements as a result of certain risks and uncertainties, including, Rexahn's lack of profitability, its auditor's going concern qualification and the need for additional capital to operate its business to develop its product candidates; the risk that Rexahn's development efforts relating to its product candidates may not be successful; the possibility of being unable to obtain regulatory approval of Rexahn's product candidates; the risk that the results of clinical trials may not be completed on time or support Rexahn's claims; demand for and market acceptance of Rexahn's drug candidates; Rexahn's reliance on third party researchers and manufacturers to develop its product candidates; Rexahn's ability to develop and obtain protection of its intellectual property; and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission. These forward-looking statements are made as of the date hereof; Rexahn assumes no obligation to update these forward-looking statements.
Source: Rexahn Pharmaceuticals, Inc.
Released September 8, 2008